

Neurizon Investor Briefings Invitation

Highlights:

- Neurizon is launching a national investor engagement series, commencing with in-person investor briefings in Sydney on Thursday, 30 April, 2026 and Perth on Monday, 4 May, 2026
- Interim Executive Chairman, Sergio Duchini, will provide an update on recent progress and upcoming milestones, followed by an interactive Q&A and networking session
- Additional dates and capital city locations to be announced shortly

16 April 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to invite shareholders and prospective investors to attend in-person investor briefings being held in Sydney during April and Perth during May.

During the briefing, Interim Executive Chairman, Sergio Duchini will present an update on recent corporate, clinical and operational progress, as well as upcoming value-defining milestones for NUZ-001.

The formal presentation will be followed by an interactive Q&A session and the opportunity to network with members of the management team over drinks and canapés.

Interim Executive Chairman, Mr Sergio Duchini commented: “We are pleased to invite investors to attend our upcoming in-person briefing sessions, which will be the first in a series of events to be held in major capital cities across Australia. We are entering a defining period for Neurizon, with a number of important clinical and corporate milestones ahead. These in-person events provide an opportunity to engage directly with our shareholder community and reinforce the strategic foundations underpinning our growth.

We look forward to announcing additional locations shortly and to meeting with as many members of the investment community as possible over the course of the year.”

Event details

Sydney		Perth	
Date	Thursday, 30 April, 2026	Date	Monday, 4 May, 2026
Time	5:00 – 7:00pm AEST	Time	5:00 – 7:00pm AWST
Location	Morgans Aurora Place, Level 21/88 Phillip St, Sydney	Location	Morgans Level 4, 50 Colin St West Perth
RSVP	By Thursday, 23 April, 2026 irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Sydney investor briefing event.	RSVP	By Friday, 24 April, 2026 irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Perth investor briefing event.

The Neurizon team looks forward to seeing all those investors who can join us at the coming events, which are part of a national investor engagement series. Additional dates and capital city locations will be announced shortly.

-ENDS-

This announcement has been authorised for release by the Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited.

For further information and questions, please contact:

Neurizon Therapeutics

Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations

Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations

Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited